Abstract:Accumulating evidence suggests that the transforming growth factor (TGF)-β pathway might be an ideal target for optimizing chimeric antigen receptor (CAR)-T-cell therapy for solid tumors. In Cellular & Molecular Immunology , Liang et al. (2024) reported that CAR-T cells expressing SMAD7 displayed favorable antitumor efficacy and a reduced risk of systemic toxicity. CAR-T cells have demonstrated promising efficacy in treating hematologic malignancies. However, this approach still faces multiple challenges in eliminating solid tumors. One challenge regarding CAR-T cell treatment for solid tumors is the immunosuppressive tumor microenvironment (TME), which is characterized by high levels of multiple inhibitory factors involving the second and third signals of T-cell activation. To overcome the immunosuppressive TME, one viable strategy is the removal or blockade of coinhibitory pathways, such as PD-1, on CAR-T cells to enhance CAR-T-cell responses and restore tumor-infiltrating lymphocytes (TIL) function [1]. Another approach entails enhancing the third signal of T-cell activation. This is achieved by the transgenic expression of cytokines or engineered cytokine receptors on CAR-T cells. This strategy not only enhances CAR-T-cell expansion and persistence but also bolsters their functionality within the immunosuppressive TME [2]. Another approach focuses on modulating the response of CAR-T cells to inhibitory TME cytokines, among which TGF-β is the most prominent. TGF-β is recognized as a pivotal immunosuppressive factor due to its impact on both T-cell and macrophage functions [3].

Inactivation of TGF-β signaling in CAR-T cells